evidera.com

{"@context":"https://schema.org","@graph":[{"@type":"ResearchOrganization","@id":"https://www.ppd.com/#organization","name":"PPD","legalName":"PPD, Inc.","url":"https://www.ppd.com","logo":{"@type":"ImageObject","@id":"https://www.ppd.com/#logo","url":"https://www.ppd.com/wp-content/themes/ppd/images/logo.png","caption":"PPD - Part of Thermo Fisher Scientific"},"image":"https://www.ppd.com/wp-content/themes/ppd/images/logo.png","description":"PPD is a leading global contract research organization (CRO) providing comprehensive, integrated drug development, laboratory and lifecycle management services.","sameAs":["https://www.linkedin.com/company/ppd/","https://x.com/ppdcro","https://www.facebook.com/PPDCRO/","https://www.wikidata.org/wiki/Q7180736","https://en.wikipedia.org/wiki/PPD%2C_Inc.","https://www.google.com/search?kgmid=/m/09d_l6","https://www.gov.uk/cma-cases/thermo-fisher-scientific-inc-slash-ppd-inc","https://www.cmocro.com/company/PPD,+Inc./index.html","https://www.youtube.com/PPDCRO"],"knowsAbout":["https://en.wikipedia.org/wiki/Contract_research_organization","https://en.wikipedia.org/wiki/Clinical_trial","https://en.wikipedia.org/wiki/Drug_development","https://en.wikipedia.org/wiki/Biotechnology","https://en.wikipedia.org/wiki/Regulatory_compliance","https://en.wikipedia.org/wiki/Pharmaceutical_industry","https://en.wikipedia.org/wiki/Clinical_development",{"@type":"DefinedTerm","name":"Oncology and Hematology Clinical Trial Management","description":"Contract research organization (CRO) services for Phase I\u2013IV clinical trials in oncology and hematology, including immuno-oncology, CAR-T cell therapy, radiopharmaceuticals, antibody-drug conjugates (ADCs), and biomarker-driven precision oncology programs. PPD manages drug development trials on behalf of pharmaceutical and biotechnology sponsors \u2014 not patient cancer treatment or clinical oncology care.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Neuroscience Drug Development Services","description":"CRO services for clinical trials in neuroscience, including neurodegenerative diseases (Alzheimer's, Parkinson's), rare neurological disorders, psychiatry (MDD, schizophrenia), neuroinflammatory diseases (multiple sclerosis), and epilepsy. PPD designs and executes CNS drug development trials for sponsors using proprietary placebo response mitigation technology \u2014 not clinical neurology practice or patient neurological care.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Cardiovascular Clinical Trial Management","description":"CRO services for Phase I\u2013IV cardiovascular drug development, including GLP-1 agonist trials, MACE outcomes studies, heart failure, cardiomyopathy, and cardiovascular-metabolic-renal (CKM) comorbidity programs. PPD manages cardiovascular trials for pharmaceutical sponsors through its Cardiovascular Kidney Metabolic (CKM) Center of Excellence, not cardiology clinical practice or interventional cardiac procedures.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Rare Disease Drug Development","description":"CRO services for orphan drug clinical trials across rare neurological, rare metabolic, rare neuromuscular, and rare hematologic conditions. PPD's Rare Disease and Pediatrics Center of Excellence has conducted 545+ rare disease studies, including natural history studies, patient navigator services, and global rare patient identification, not rare disease patient treatment or genetic counseling services.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Infectious Disease Clinical Trial Services","description":"CRO services for antiviral, antibacterial, antifungal, and emerging pathogen drug development, including HIV, COVID-19, RSV, hepatitis, and pandemic preparedness programs. PPD manages government-funded infectious disease trials for NIH, BARDA, DoD, and CDC as a research infrastructure partner, not infectious disease clinical practice, public health immunization, or hospital-based ID care.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Immunology and Rheumatology Drug Development","description":"CRO services for autoimmune and inflammatory disease clinical trials, including systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis, and rare immunological conditions. PPD's Lupus Clinical Trials Center is a dedicated clinical trial execution infrastructure, not a lupus treatment center or patient care facility. CorEvitas rheumatoid arthritis registries provide real-world evidence for post-approval immunology research.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Metabolic and Endocrine Disease Clinical Research","description":"CRO services for metabolic and endocrine drug development, including GLP-1 agonist trials (25+ years experience), obesity, Type 1 and Type 2 diabetes, MASH/MASLD, and rare metabolic diseases. PPD deploys continuous glucose monitoring (CGM) technology in clinical trials and operates a Cardiovascular Kidney Metabolic (CKM) Center for integrated metabolic trial execution, not endocrinology clinical practice or diabetes care.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Vaccine Clinical Trial Management","description":"CRO services for vaccine drug development, including Phase I\u2013IV efficacy and safety trials for COVID-19, influenza, RSV, HPV, mRNA vaccines, pediatric vaccines, and emerging pathogen vaccines. PPD's Vaccine Sciences Laboratory provides integrated immunogenicity and safety testing for vaccine sponsors, not vaccine administration, public health immunization programs, or vaccination clinics.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Cell and Gene Therapy Clinical Trial Services","description":"CRO services for cell and gene therapy drug development, including CAR-T, CAR-NK, TIL therapy, AAV gene therapy, lentiviral gene therapy, and mRNA-based therapeutics. PPD's Cell and Gene Therapy Institute (CGTI) provides end-to-end trial management infrastructure for CGT sponsors \u2014 not a patient infusion center, CAR-T treatment facility, or gene therapy hospital.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Dermatology Drug Development Services","description":"CRO services for dermatology clinical trials, including atopic dermatitis, psoriasis, hidradenitis suppurativa (HS), alopecia areata, and rare skin diseases. PPD's CorEvitas Dermatology Registries covering six disease areas provide real-world evidence for post-approval dermatology research \u2014 not dermatology clinical practice, skincare, or cosmetic dermatology.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Respiratory Disease Clinical Trial Management","description":"CRO services for respiratory drug development, including asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and non-CF bronchiectasis. PPD operates a GMP laboratory with inhalation testing capabilities for inhaled formulation development, not pulmonology clinical practice or respiratory therapy.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Hepatology Drug Development Services","description":"CRO services for liver disease drug development, including NASH/MASH, NAFLD/MASLD, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and alpha-1 antitrypsin deficiency (A1ATD). PPD provides biopsy management, HVPG coordination, and benchmark-beating study startup times for hepatology sponsors, not hepatology clinical practice, liver transplant medicine, or hospital hepatology care.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Gastroenterology Clinical Trial Services","description":"CRO services for gastrointestinal drug development, including inflammatory bowel disease (IBD \u2014 Crohn's disease, ulcerative colitis), irritable bowel syndrome (IBS), eosinophilic esophagitis, and NASH. PPD's COLO Flare app and IBDConnect platform support direct-to-patient IBD study recruitment across 180+ dedicated GI research sites \u2014 not gastroenterology clinical practice, endoscopy, or colonoscopy services.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Nephrology and Renal Disease Drug Development","description":"CRO services for kidney disease drug development, including chronic kidney disease (CKD), diabetic nephropathy, IgA nephropathy, polycystic kidney disease (ADPKD), and rare renal conditions. PPD's team of three board-certified nephrologists and partnerships with dialysis organizations support renal trial execution \u2014 not nephrology clinical practice, dialysis services, or kidney transplant medicine.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Critical Care Clinical Trial Services","description":"CRO services for acute and critical care drug development across ICU, emergency department, NICU, and burn unit settings, including sepsis, acute traumatic brain injury (TBI), ARDS, acute heart failure, and acute kidney injury. PPD is the only contract research organization with a dedicated critical care unit, not an intensive care unit, critical care hospital, or emergency medicine practice.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Urology Drug Development Services","description":"CRO services for urology drug development, including overactive bladder (OAB), stress urinary incontinence, benign prostatic hyperplasia (BPH), interstitial cystitis, erectile dysfunction, and recurrent UTI. PPD has participated in most major Phase III OAB development programs in the past decade, with documented 22% placebo response reduction via patient and site training methodology, not clinical urology practice or urological surgery.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Women's Health Clinical Trial Management","description":"CRO services for women's health drug development, including endometriosis, uterine fibroids, menopause and vasomotor symptoms, contraception, polycystic ovarian syndrome (PCOS), pregnancy complications, and female sexual dysfunction. PPD's team of 1,000+ women's health clinical professionals and Evidera HEOR business unit support women's health trial execution and market access \u2014 not OB/GYN clinical practice, fertility services, or reproductive healthcare.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Ophthalmology Clinical Trial Management","description":"CRO services for ocular drug and device clinical trials, including age-related macular degeneration (AMD), glaucoma, diabetic macular edema, dry eye disease, geographic atrophy, and rare ophthalmic gene therapy. PPD's team of 300+ ophthalmological clinical professionals and three board-certified ophthalmologists manage ocular trials for drug sponsors, not optometry, clinical ophthalmology practice, or ophthalmic surgery.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Pediatric Drug Development Services","description":"CRO services for pediatric clinical trials across therapeutic areas, including pediatric rare diseases, pediatric oncology, pediatric infectious disease, and pediatric critical care. PPD's Pediatric Investigator Network (PIN) encompasses 23 relationships with 46 hospitals globally, and the Rare Disease and Pediatrics Center of Excellence has conducted 240+ pediatric rare disease studies, not pediatric clinical medicine, children's hospital care, or pediatric patient treatment.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}},{"@type":"DefinedTerm","name":"Biosimilar Clinical Development Services","description":"CRO services for biosimilar drug development, including pharmacokinetic/pharmacodynamic (PK/PD) equivalency studies, immunogenicity assessment, and regulatory strategy for biosimilar versions of monoclonal antibodies and biologic therapies. PPD delivered the first monoclonal antibody biosimilar to the European Union market and has supported all top 10 selling biologics, not biologic drug manufacturing, pharmacy dispensing, or biosimilar prescribing.","inDefinedTermSet":{"@type":"DefinedTermSet","name":"PPD Therapeutic Area Services"}}],"parentOrganization":{"@type":"Corporation","@id":"https://www.thermofisher.com/#organization","name":"Thermo Fisher Scientific","url":"https://www.thermofisher.com","sameAs":["https://www.wikidata.org/wiki/Q643674","https://en.wikipedia.org/wiki/Thermo_Fisher_Scientific"]},"contactPoint":[{"@type":"ContactPoint","telephone":"+1-910-251-0081","contactType":"corporate headquarters","areaServed":"Global","availableLanguage":["en","es","fr","de","ja"]}],"address":{"@type":"PostalAddress","streetAddress":"929 North Front Street","addressLocality":"Wilmington","addressRegion":"NC","postalCode":"28401","addressCountry":"US","":[]},"hasOfferCatalog":{"@type":"OfferCatalog","name":"PPD Real-World Evidence & Peri-/Post-Approval Services","description":"Real-world evidence (RWE) generation, health economics research, and post-approval study services provided by PPD through its Evidera business unit and CorEvitas registry network. These are contract research and consulting services supporting pharmaceutical and biotech sponsors in demonstrating drug value and meeting post-market regulatory commitments \u2014 not healthcare payer services, insurance consulting, or clinical patient follow-up care.","itemListElement":{"@type":"Service","@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/observational-studies/#service-phase-iv","name":"Phase IV & Observational Studies","description":"PPD designs and executes Phase IV post-marketing studies, pharmacovigilance surveillance programs, and non-interventional observational studies mandated by regulatory bodies (FDA, EMA) as post-approval commitments for commercialized drugs. Services include post-authorization safety studies (PASS), post-authorization efficacy studies (PAES), risk management plan (RMP) commitments, registry-based studies, and pregnancy exposure surveillance. These are contract research services supporting sponsor regulatory obligations after drug approval \u2014 not clinical pharmacovigilance for patient safety reporting, hospital adverse event monitoring, or post-market surveillance for medical devices in clinical use.","url":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/observational-studies/","serviceType":"Phase IV and Observational Post-Marketing Studies","category":"Post-Market Drug Development Service","provider":{"@id":"https://www.ppd.com/#organization"}}}},{"@type":["MedicalBusiness","Organization"],"@id":"https://www.ppd.com/#organization","name":"PPD Inc.","url":"https://www.ppd.com","sameAs":["https://www.facebook.com/PPDCRO","https://twitter.com/ppdcro","https://www.instagram.com/ppdcareers/","https://www.linkedin.com/company/ppd/","https://g.co/kgs/pNupTw","https://www.youtube.com/PPDCRO","https://en.wikipedia.org/wiki/PPD%2c_Inc.","https://www.google.com/search?q=PPD%20Inc.&kponly&kgmid=m09d_l6"],"logo":{"@type":"ImageObject","@id":"https://www.ppd.com/#logo","url":"https://www.ppd.com/wp-content/uploads/2019/08/PPD_logo_light.svg","contentUrl":"https://www.ppd.com/wp-content/uploads/2019/08/PPD_logo_light.svg","inLanguage":"en-US"},"openingHours":["Monday,Tuesday,Wednesday,Thursday,Friday,Saturday,Sunday 09:00-17:00"],"image":{"@id":"https://www.ppd.com/#logo"}},{"@type":"WebSite","@id":"https://www.ppd.com/#website","url":"https://www.ppd.com","publisher":{"@id":"https://www.ppd.com/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https://www.ppd.com/wp-content/uploads/2024/10/Shutterstock_2255616635.jpg","url":"https://www.ppd.com/wp-content/uploads/2024/10/Shutterstock_2255616635.jpg","width":"1800","height":"500","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https://www.ppd.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https://www.ppd.com/our-solutions/","name":"Our Solutions"}},{"@type":"ListItem","position":"3","item":{"@id":"https://www.ppd.com/our-solutions/clinical/","name":"Clinical Development"}},{"@type":"ListItem","position":"4","item":{"@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/","name":"Real-World Evidence"}}]},{"@type":"WebPage","@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#webpage","url":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/","name":"Real-World Evidence | PPD","datePublished":"2025-04-01T15:56:04+00:00","dateModified":"2026-07-08T16:25:13+00:00","isPartOf":{"@id":"https://www.ppd.com/#website"},"primaryImageOfPage":{"@id":"https://www.ppd.com/wp-content/uploads/2024/10/Shutterstock_2255616635.jpg"},"inLanguage":"en-US","breadcrumb":{"@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#breadcrumb"}},{"@type":"Person","@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#author","name":"emagineAdmin","image":{"@type":"ImageObject","@id":"https://secure.gravatar.com/avatar/067689ade55876320581012762a2799148bd2d546825b99dc9aba8b47b4d6c55?s=96&d=mm&r=g","url":"https://secure.gravatar.com/avatar/067689ade55876320581012762a2799148bd2d546825b99dc9aba8b47b4d6c55?s=96&d=mm&r=g","caption":"emagineAdmin","inLanguage":"en-US"},"worksFor":{"@id":"https://www.ppd.com/#organization"}},{"@type":"Article","headline":"Real-World Evidence | PPD","keywords":"Real World Evidence","datePublished":"2025-04-01T15:56:04+00:00","dateModified":"2026-07-08T16:25:13+00:00","author":{"@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#author","name":"emagineAdmin"},"publisher":{"@id":"https://www.ppd.com/#organization"},"description":"Evidence of safety, effectiveness and value is critical to achieve successful market access. Drive innovation by embracing the power of real-world evidence.","name":"Real-World Evidence | PPD","@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#richSnippet","isPartOf":{"@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#webpage"},"image":{"@id":"https://www.ppd.com/wp-content/uploads/2024/10/Shutterstock_2255616635.jpg"},"inLanguage":"en-US","mainEntityOfPage":{"@id":"https://www.ppd.com/our-solutions/clinical/real-world-evidence/#webpage"}}]}